<DOC>
	<DOCNO>NCT01710631</DOCNO>
	<brief_summary>A six-month study determine safety efficacy additional open-label extension determine long-term safety eszopiclone treatment adult subject primary insomnia .</brief_summary>
	<brief_title>Twelve Month Study Safety Eszopiclone Adult Subjects With Insomnia</brief_title>
	<detailed_description>A six month , randomize , double-blind six month open-label extension , multi-center , outpatient study determine safety eszopiclone treatment adult subject primary insomnia . Approximately 800 subject randomize use 3:1 ratio receive one two treatment , eszopiclone 3 mg placebo , 6 month . All subject complete 6 month treatment eligible receive open-label 3 mg eszopiclone additional 6 month . Subjects allow stay study 12 month .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Eszopiclone</mesh_term>
	<criteria>Subject meet Diagnostic Statistical Manual Mental Disorders , 4th Edition ( DSMIV ) criteria primary insomnia report sleep 6.5 hour per night and/or take 30 minute night fall asleep least one month prior screen . Subject 21 64 year age ( inclusive ) screening . Both male female eligible participate . Subject provide write informed consent indicate purpose study understood . The subject willing adhere regimen study procedure describe protocol . Females childbearing potential must willingly sign `` Women ChildBearing Potential Informed Consent '' addendum . Females consider childbearing potential must surgically sterile great oneyear postmenopausal , define complete cessation menstruation least one year . Subject 's physical examination , include brief neurological examination , show clinically significant abnormal finding screen . Subject know clinically significant abnormal laboratory finding screen . Subject clinically significant Electrocardiography ( ECG ) abnormalities screen . Subject clinically significant unstable medical abnormality , chronic disease , history clinically significant abnormality cardiovascular , respiratory , hepatic , renal system . Subject history , current malignancy except nonmelanomatous skin cancer . Subject objective evidence active thyroid disease screening . Subjects thyroid replacement therapy include long dose stable â‰¥ 3 month . Subject DSMIV Axis I psychiatric diagnosis Sexual Gender Identity Disorders , Axis II Personality Disorders ( schizotypal , schizoid , borderline personality disorder ) . Other nonpsychotic Axis I disorder except dementia delirium consider casebycase basis . Subject know sensitivity racemic zopiclone , benzodiazepine , sedative hypnotic , substance contain formulation , hospitalize allergic condition ( e.g . recurrent dermatitis , drug hypersensitivity , drug allergy , etc. ) . Subject difficulty sleep initiation maintenance associate known sleep difficulty ( e.g . sleep apnea , restless leg syndrome , ( RLS ) periodic leg movement syndrome ( PLMS ) ) , condition , may , affect sleep ( e.g. , chronic pain , Benign prostatic hyperplasia ( BPH ) , etc. ) . Subject history substance abuse past 10 year substance dependence time ; positive urine drug test screening . Subject test positive screening hepatitis B surface antigen , hepatitis C antibody history positive result . Subject know seropositive Human immunodeficiency virus ( HIV ) . Female subject pregnant , lactate within 6 month postpartum . Subject disorder history condition ( e.g. , malabsorption , gastrointestinal surgery ) may interfere drug absorption , distribution , metabolism , excretion . Subject use drug know suspected affect hepatic renal clearance capacity within period 30 day prior screen . Subject selfreported consumption two alcoholic beverage daily , 14 alcoholic beverage weekly , five alcoholic beverage give day . Subject take psychotropic medication medication know affect sleep within 3 day prior screen visit anticipate need type medication doubleblind treatment . Subject participate investigational study within 30 day prior screen . Subject take herbal supplement , purported central nervous system effect , ( tablet , powder , extract tincture ) combination product herbs melatonin within 14 day prior screen St. John 's Wort within 30 day prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Sleep</keyword>
</DOC>